Blog
RSS FeedPosted by Michael Wonder on 26 May 2021
NICE terminates yet another two appraisals
26 May 2021 - This is becoming far too commonplace. ...
Posted by Michael Wonder on 20 May 2021
NICE nod for BMS’ Opdivo in advanced oesophageal cancer
14 May 2021 - The UK NICE has recommended Bristol Myers Squibb’s Opdivo for the treatment of unresectable advanced oesophageal ...
Posted by Michael Wonder on 20 May 2021
NICE turns down Janssen's Erleada
20 May 2021 - NICE has published draft guidance rejecting Janssen's Erleada (apalutamide) with androgen deprivation therapy for treating prostate ...
Posted by Michael Wonder on 19 May 2021
NICE terminates yet another appraisal of a cancer medicine
19 May 2021 - This time it is for a new medicine for patients with multiple myeloma. ...
Posted by Michael Wonder on 17 May 2021
Optimising managed access: lessons from the Cancer Drugs Fund
14 May 2021 - The desire, opportunity, and willingness to increase access to potentially life saving cancer treatments has mounted in ...
Posted by Michael Wonder on 14 May 2021
Colorectal cancer patients with rare mutations to benefit from life-extending treatment
14 May 2021 - NICE recommends pembrolizumab for colorectal cancer patients with rare mutations. ...
Posted by Michael Wonder on 07 May 2021
Avelumab not recommended as a maintenance treatment of urothelial cancer after platinum-based chemotherapy
7 May 2021 - NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of locally advanced or ...
Posted by Michael Wonder on 06 May 2021
Preliminary NICE 'no' for Merck's Bavencio
6 May 2021 - NICE has issued a preliminary rejection of NHS funds for use of Merck Serono's Bavencio (avelumab) ...
Posted by Michael Wonder on 22 Apr 2021
Delcath Systems announces revised NICE guidance for Chemosat in the United Kingdom
21 April 2021 - Recommends special arrangement designation which increases reimbursement options. ...
Posted by Michael Wonder on 21 Apr 2021
Chemotherapy-free treatment option to be offered to patients with England’s most common leukaemia
20 April 2021 - Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated ...
Posted by Michael Wonder on 20 Apr 2021
NICE draft guidance provides Cancer Drugs Fund first in Europe access to new treatment option for advanced breast cancer
20 April 2021 - NICE has today published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund for ...
Posted by Michael Wonder on 12 Apr 2021
Prevalence of immature survival data for anti-cancer drugs presented to the National Institute for Health and Care Excellence and impact on decision-making
12 April 2021 - This research aims to explore how often NICE uses immature overall survival data to inform reimbursement ...
Posted by Michael Wonder on 07 Apr 2021
Thousands to benefit from five minute breast cancer treatment
6 April 2021 - NHS England is rolling out an injection that dramatically cuts the amount of time breast cancer ...
Posted by Michael Wonder on 31 Mar 2021
NICE publishes guidance on new use for Kisqali
31 March 2021 - NICE has published an evidence base recommendation on ribociclib succinate (Kisqali) for the treatment of adults ...
Posted by Michael Wonder on 22 Mar 2021
Triple therapy recommended by NICE for patients with multiple myeloma
22 March 2021 - The therapy has been recommended after a confidential discount was agreed between NHS England and the drug ...